Income Statement Presentation 2023

Changes to the development pipeline Q4 2022 update Roche New to phase I New to phase II New to phase III 1 NME: 2 NMES: RG1662 basmisanil - Dup 15q syndrome 6 NMES: RG6209 NME - retinal disease RG6421 TMEM16A potentiator - cystic fibrosis RG6524 NME - solid tumors RG6411 NME - solid tumors CHU anti-HLA-DQ2.5 x gluten peptides - celiac disease CHU RAY 121 - immunology 1 NME (moved from phase III): RG6042 tominersen - Huntington's RG6179 anti-IL-6 - UME RG6330 KRAS G12C - 2L NSCLC New to registration 1 NME (US): RG6026 glofitamab - 3L+ DLBCL 1 AI (US & EU): RG7446 Tecentriq SC - subcutaneous formulation, all approved indications Removed from phase I Removed from phase II 1 NME: 2 NMES: RG7880 efmarodocokin alfa - aGVHD Status as of February 2, 2023 Removed from phase III Approvals RG1450 gantenerumab - prodromal to mild Alzheimer's RG7440 ipatasertib + abiraterone - 1L CRPC 5 Als: RG7446 Tecentriq +chemo - 1L MUC I RG7446 Tecentriq + cabozantinib - 2L NSCLC RG3502 Kadcyla + Tecentriq - 2L+ HER-2+ PD-L1+ MBC RG1450 gantenerumab - preclinical Alzheimer's RG6354 zinpentraxin alfa (PRM-151) - IPF 1 NME (US): RG7828 Lunsumio - 3L+ FL 3 Als (US): RG7446 Tecentriq - ASPS RG1569 Actemra - COVID-19 pneumonia RG7421 Cotellic - histiocytosis 2 Als (EU): RG6152 Xofluza - influenza pediatric RG6013 Hemlibra - moderate hemophilia A 76

View entire presentation